Skip to content
NewsBlazeAU – Lifestyle
Author:
Prolium Bioscience, Inc.
Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
June 22, 2026